Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Sep-Oct;91(5 suppl 1):48-50.
doi: 10.1590/abd1806-4841.20164527.

Scleromyxedema: clinical diagnosis and autopsy findings

Affiliations
Case Reports

Scleromyxedema: clinical diagnosis and autopsy findings

Ana Carolina Bulhões Sala et al. An Bras Dermatol. 2016 Sep-Oct.

Abstract

Scleromyxedema is a rare chronic cutaneous mucinosis of unknown etiology. It is characterized by papular eruption and scleroderma with microscopic evidence of mucin deposition, fibroblast proliferation, and fibrosis. Most patients with scleromyxedema have monoclonal gammopathy and systemic manifestations resulting in significant morbidity and mortality. Several types of treatment have been reported with partial or inconsistent responses. Despite showing unpredictable evolution, systemic consequences of scleromyxedema and treatment side effects may result in death. We describe a rare case of a patient with scleromyxedema without paraproteinemia with systemic involvement that evolved to death despite treatment with cyclophosphamide.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1
Figure 1
Papulareruption associated with erythema on the back and neck
Figure 2
Figure 2
Coalescing normochromic papules, some in linear arrangement, and sclerodermiform surrounding skin
Figure 3
Figure 3
Erythematous areas interspersed with pallor and evidence of proximal weakness
Figure 4
Figure 4
Positive colloi - dal iron staining, identifying mucopolysaccharides between the collagen bands (400x)
Figure 5
Figure 5
Dense superficial perivascular inflammatory infiltrates (HE, 100x)

Similar articles

Cited by

References

    1. Heymann WR. Scleromyxedema. J Am Acad Dermatol. 2007;57:890–891. - PubMed
    1. Guarenti I, Sebastiani V, Pinto G, de Souza PR, de Almeida H., Jr Successful treatment of scleromyxedema with oral thalidomide. Int J Dermatol. 2013;52:631–632. - PubMed
    1. Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, Cribier B, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69:66–72. - PubMed
    1. Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol. 2009;60:1037–1041. - PubMed
    1. Fleming KE, Virmani D, Sutton E, Langley R, Corbin J, Pasternak S, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol. 2012;39:508–517. - PubMed

Publication types

LinkOut - more resources